XML 17 R6.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Cash flows from operating activities:    
Net loss $ (2,893,002) $ (1,622,745)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1,218,948 989,562
Interest from amortization of loan issuance costs 38,312 45,833
Amortization of fair value of loan 52,544 0
Change in fair value of acquisition earnout liabilities 1,282,529 0
Loss on disposal of property and equipment 3,999 78,437
Stock-based compensation on stock options, RSUs & RSAs, net 359,661 264,475
Provision for credit losses (5,390) 0
Change in operating lease assets and liabilities (60,448) (25,779)
Inventory write-offs to allowance 0 21,770
Deferred taxes 555 5,558
Changes in operating assets and liabilities, net of acquisitions:    
Trade accounts receivable (133,679) (267,909)
Other current assets 27,800 128,959
Inventories (3,335) (260,915)
Prepaid expenses and deposits 127,786 (91,079)
Accounts payable and accrued liabilities (1,159,122) (966,368)
Net cash used in operating activities (1,142,842) (1,700,201)
Cash flows from investing activities:    
Purchase of property and equipment (77,014) (79,732)
Proceeds from sale of equipment 0 10,648
Net cash used in investing activities (77,014) (69,084)
Cash flows from financing activities:    
Proceeds from sale of common stock from Employee Stock Purchase Plan 0 10,372
Proceeds from issuance of common stock under private equity placement, net of fees 7,894,045 0
Deferred payment for acquisition of Visimid 0 (125,000)
Borrowings on loans payable 0 3,000,000
Loan issuance costs 0 (300,000)
Payments on loans payable (57,107) (53,695)
Repayment of finance lease obligations (55,398) (43,444)
Net cash provided by financing activities 7,781,540 2,488,233
Effect of exchange rate on cash and cash equivalents 68,698 81,421
Change in cash and cash equivalents 6,630,382 800,369
Cash and cash equivalents, beginning of period 4,877,036 3,480,268
Cash and cash equivalents, end of period 11,507,418 4,280,637
Supplemental disclosure of cash flow information:    
Interest paid in cash 177,963 20,990
Income taxes paid 56,282 16,903
Supplemental disclosure of non-cash investing & financing activities:    
Operating right-of-use assets acquired in exchange for operating lease liabilities 435,733 0
Issuance of common stock for acquisition of Visimid $ 350,000 $ 350,000